1472. Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019)
Authors: Sader Helio S , Carvalhaes Cecilia G , Streit Jennifer M , Huband Michael D , Shorttidge Dee , Mendes Rodrigo E , Castanheira Mariana 
Published: January 2021

Background

The SENTRY Antimicrobial Surveillance Program monitors the frequency of occurrence and antimicrobial susceptibility of organisms from various infection types worldwide. In this investigation, we evaluate the results for organisms isolated from patients hospitalized with bacterial pneumonia.

Methods

28,918 bacterial isolates were consecutively collected (1/patient) in 2016-2019 from 121 medical centers located in the United States (US; n=17,770; 82 centers), western Europe (W-EU; n=7,966; 25 centers from 10 nations), and eastern Europe (E-EU; n=3,182; 14 centers from 11 nations). Organisms were tested for susceptibility by reference broth microdilution methods in a central laboratory.

Results

The rank order of organisms varied markedly among geographic regions (Table). Gram-negative bacilli (GNB) represented 69.1%, 76.3%, and 88.6% of organisms; and non-fermentative (NF) GNB represented 34.6%, 26.9%, and 51.8% of organisms in US, W-EU, and E-EU, respectively. Among NF-GNB, P. aeruginosa ranked first in W-EU and E-EU and second in the US, A. baumannii ranked third in E-EU, and S. maltophilia was among the top 8 in all 3 regions (fifth in the US). P. aeruginosa susceptibility to piperacillin-tazobactam and meropenem (MEM) were 76.1% and 74.8% in the US, 75.4% and 76.9% in W-EU, and 57.4% and 48.3% in E-EU, respectively. Only 10.4% of A. baumannii isolates from E-EU were MEM-susceptible compared to 45.8% in W-EU and 58.7% in the US. MRSA rates in the US improved from 44.8% in 2016 to 40.2% in 2019 (p&lt; 0.05). Overall MRSA rates were 21.4% in W-EU, and 28.7% in E-EU. CRE rates decreased continuously in the US from 3.0% in 2016 to 1.7% in 2019 (p &lt; 0.05; 2.4% overall) and were higher E=EU (16.6%) than W-EU (2.2%). Among K. pneumoniae, susceptibility to ceftriaxone and MEM were 80.7% and 94.9% in the US, 70.1% and 90.7% in W-EU, and 34.5% and 70.4% in E-EU, respectively. Among E. coli, susceptibility to ceftriaxone and levofloxacin were 71.4% and 55.0% in the US, 79.2% and 71.2% in W-EU, and 62.6% and 55.9% in E-EU, respectively.

Table 1

Conclusion

Rank order and antimicrobial susceptibility of bacteria isolated from patients with pneumonia varied widely by geographic region. Multidrug-resistant NF-GNB represented an important cause of pneumonia in US and Europe.

Disclosures

Helio S. Sader, MD, PhD, A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)Allergan (Research Grant or Support)Allergan (Research Grant or Support)Allergan (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Melinta (Research Grant or Support)Merck (Research Grant or Support)Merck (Research Grant or Support)Paratek Pharma, LLC (Research Grant or Support)Pfizer (Research Grant or Support) Cecilia G. Carvalhaes, MD, PhD, A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)Allergan (Research Grant or Support)Cidara Therapeutics (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Fox Chase Chemical Diversity Center (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Merck (Research Grant or Support)Merck (Research Grant or Support)Merck & Co, Inc. (Research Grant or Support)Pfizer (Research Grant or Support) Jennifer M. Streit, BS, A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)Allergan (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Merck (Research Grant or Support)Paratek Pharma, LLC (Research Grant or Support) Rodrigo E. Mendes, PhD, A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)Allergan (Research Grant or Support)Allergan (Research Grant or Support)Basilea Pharmaceutica International, Ltd (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Department of Health and Human Services (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Merck (Research Grant or Support)Merck (Research Grant or Support)Pfizer (Research Grant or Support) Mariana Castanheira, PhD, 1928 Diagnostics (Research Grant or Support)A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support)Allergan (Research Grant or Support)Allergan (Research Grant or Support)Amplyx Pharmaceuticals (Research Grant or Support)Cidara Therapeutics (Research Grant or Support)Cidara Therapeutics (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Cipla Ltd. (Research Grant or Support)Fox Chase Chemical Diversity Center (Research Grant or Support)GlaxoSmithKline (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Melinta Therapeutics, Inc. (Research Grant or Support)Merck (Research Grant or Support)Merck (Research Grant or Support)Merck & Co, Inc. (Research Grant or Support)Merck & Co, Inc. (Research Grant or Support)Paratek Pharma, LLC (Research Grant or Support)Pfizer (Research Grant or Support)Qpex Biopharma (Research Grant or Support)